Understanding Tirzepatide: Benefits, Side Effects, and Uses for Diabetes and Weight Loss
- Tirzepatide, marketed under the brand names Mounjaro for type 2 diabetes and Zepbound for obesity, represents a new class of medication known as glucagon-like peptide 1 (GLP-1) and...
- The medication is administered as a pill or a once-weekly injection into the thigh, abdomen, or upper arm.
- Tirzepatide mimics two incretin hormones: GLP-1, found in the upper gut, and GIP, found in the lower gut.
Tirzepatide, marketed under the brand names Mounjaro for type 2 diabetes and Zepbound for obesity, represents a new class of medication known as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. This dual-action medication is designed to manage blood sugar levels in people with type 2 diabetes and facilitate significant weight loss in individuals with obesity.
The medication is administered as a pill or a once-weekly injection into the thigh, abdomen, or upper arm. Doses range from 2.5 milligrams (mg) to 15 mg and are typically titrated, meaning the dose is increased gradually over several months to help the body adjust and reduce the risk of side effects.
How Tirzepatide Works
Tirzepatide mimics two incretin hormones: GLP-1, found in the upper gut, and GIP, found in the lower gut. Together, these hormones stimulate the secretion of insulin after a meal, which helps the body use or store glucose more effectively. This is particularly beneficial for those with type 2 diabetes, whose bodies cannot handle insulin efficiently, often leading to hyperglycemia.
According to Florencia Halperin, MD, a Boston-based endocrinologist and chief medical officer of Form Health, these receptors are located in the pancreas, where they increase insulin secretion, and in the brain’s appetite centers. GLP-1 specifically slows the emptying of the stomach, allowing patients to feel full sooner and for longer periods, while GIP acts on fat cells in various ways.
This dual mechanism distinguishes tirzepatide from semaglutide (sold as Ozempic and Wegovy), which is a GLP-1 receptor agonist. While both trigger insulin production when blood sugar rises, tirzepatide’s addition of the GIP hormone means it affects not only appetite and stomach emptying but also how the body deposits fat.
Effectiveness in Type 2 Diabetes Management
The U.S. Food and Drug Administration (FDA) approved Mounjaro for the treatment of type 2 diabetes in May 2022. This approval was based on five randomized clinical trials which indicated the drug is highly effective when used alongside diet and exercise.
The FDA noted that patients receiving the maximum recommended dose of 15 mg saw their hemoglobin A1C levels—a two- to three-month average of blood sugar—lowered by 1.6 percentage points more than a placebo when used as a stand-alone therapy. When combined with long-acting insulin, the reduction was 1.5 percentage points more than the placebo.
Further research comparing tirzepatide to other diabetes medications found that the 15 mg dose lowered A1C levels more than several alternatives: 0.5 percentage points more than semaglutide, 0.9 percentage points more than the long-acting insulin degludec (Tresiba), and 1.0 percentage point more than the long-acting insulin glargine (Lantus).
Weight Loss Outcomes and Clinical Trials
Tirzepatide has shown significant efficacy for weight loss in both individuals with and without type 2 diabetes. In November 2023, the FDA approved the drug for weight loss under the brand name Zepbound. Research indicates that when combined with diet and exercise, the medication helped participants lose an average of 27 percent of their body weight over 18 months.
The SURMOUNT-1 randomized trial involved more than 2,500 people without diabetes who had obesity (BMI of 30 or higher) or a weight-linked disease with a BMI of 27 or higher. Over 72 weeks, more than 97 percent of participants lost weight. Those receiving the 15 mg dose saw an average weight reduction of 22.5 percent, compared to 2.4 percent in the placebo group. The 15 mg group experienced a reduction in waist circumference of 19.9 centimeters (7.8 inches), while the placebo group saw a reduction of 3.4 centimeters (1.3 inches).
In a separate SURMOUNT trial focusing on people with type 2 diabetes and a BMI of 27 or higher, participants taking the 10 mg dose lost an average of 30 lb (13.4 percent of their body weight), and those on the 15 mg dose lost an average of 34.4 lb (15.7 percent), compared to 7 lb (3.3 percent) in the placebo group.
Louis Aronne, MD, an endocrinologist and director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City, describes the Mounjaro results as
spectacular,and for those in the highest weight categories, comparable with bariatric surgery results.It’s really quite a remarkable finding.Coauthor of the New England Journal of Medicine study on tirzepatide for obesity treatment
Lifestyle Integration and Requirements
Medical professionals emphasize that tirzepatide is not a standalone solution for weight loss. Participants in the SURMOUNT-1 trial adhered to a regimen that included at least 150 minutes of physical activity per week and a daily caloric deficit of 500 calories, supported by regular lifestyle counseling.
These medications are less likely to work without changes to underlying habits and lifestyle,says Jessica Cutler, MD, a bariatric surgeon at Mercy Medical Center in Baltimore.I believe that without those changes, weight regain is very likely if the medication is stopped.Jessica Cutler, MD
Safety, Side Effects, and Contraindications
The most common side effects associated with tirzepatide are gastrointestinal. These include:
- Nausea (experienced by one-third of SURMOUNT-1 participants, typically mild and decreasing over time)
- Constipation
- Diarrhea
- Decreased appetite
- Indigestion
- Stomach pain
- Vomiting
More severe risks include intestinal blockages, which the FDA has identified as a potential safety issue for all GLP-1 receptor agonists. In the SURMOUNT trial, gallbladder inflammation occurred in fewer than 1 percent of participants taking tirzepatide.
Tirzepatide carries a safety warning regarding the potential for thyroid tumors, including thyroid cancer. Florence Comite, MD, founder of the Comite Center for Precision Medicine and Healthy Longevity, states that the drug should not be used by patients with a family history of certain thyroid cancers, such as medullary thyroid carcinoma, or those with multiple endocrine neoplasia type 2.
tirzepatide is not indicated for people with type 1 diabetes, although a 12-week clinical trial suggested it was superior to a placebo for weight loss in that population; however, further studies are required.
Demographic Research and Other Benefits
Research has explored the drug’s effectiveness across different ethnic groups. Dr. Louis Aronne noted that the SURPASS-J trials in Japanese populations and data from Hispanic/Latino participants in the SURPASS-2 trial show that tirzepatide works just as well in these communities. He added that while outcomes appear equivalent in terms of glucose reduction, more work is needed to ensure similar results across other ethnic groups.
Beyond blood sugar and weight, the SURPASS trials found that tirzepatide helped lower systolic blood pressure in people with type 2 diabetes. Participants saw drops between 4.2 mmHg and 12.6 mmHg after 40 to 42 weeks, a result largely attributed to weight loss.
Due to its effect on delaying gastric emptying, tirzepatide may affect the absorption of other medications. Patients are advised to consult their healthcare provider regarding all current medications to avoid potential interactions.